Exchange: NASDAQ·Updated 04:10 PM EDT
MDWD logo

MDWD MediWound Ltd

$12.54
$0.12
(0.97%)
Today
Closed $12.54
$0.00
(0.00%)
After Hours
EarningsNov 19
Mkt Cap$160.35M
Vol92,646.00

About MDWD

MediWound Ltd. is a biopharmaceutical company, which engages in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Its product NexoBrid, is an orphan biologic for eschar removal in severe burns. The company was founded by Lior Rosenberg and Marian Gorecki in January 2000 and is headquartered in Yavne, Israel.
62

Bullish Sentiment

How do you feel about MDWD?

Lambster2
$MDWD MediWound Ltd. (NASDAQ: MDWD) Buy (1) Price Target: $25.00 EscharEx Approaching Its VALUE Inflection; A Potential Wound-Care Disruptor THE TD COWEN INSIGHT We see an increasingly attractive setup into the Phase 3 VALUE interim analysis. Positive EscharEx data could validate its differentiated 4-5 day debridement profile, challenge Santyl’s entrenched ~$400M franchise, unlock a potentially much larger $1B+ VLU opportunity, and generate substantial strategic interest. Reiterate Buy.
2
focafoca99
$MDWD noted an independent DSMB recommendation to continue its Phase III VALUE study without modification.
1
laaarsas
$MDWD Why should they be successful with time to wound closure in the new study? I'm not sure I see why it should happen.
focafoca99
$MDWD awarded an extra $3.3 million from the U.S. Department of War to develop a room-temperature-stable NexoBrid formulation.
DonCorleone77
$MDWD MediWound awarded additional $3.3M from DOW to advance NexoBrid MediWound announced that the U.S. Department of War, DOW, has awarded the Company an additional $3.3M in non-dilutive funding to advance the development of a room-temperature-stable formulation of NexoBrid as a non-surgical debridement solution for battlefield burn care. The supplemental award raises the total program budget to $21.8M. The program is intended to support development of the room-temperature-stable formulation through submission of an IND application to the U.S. Food and Drug Administration.

Advertisement|Remove ads.